{"protocolSection": {"identificationModule": {"nctId": "NCT03556761", "orgStudyIdInfo": {"id": "829444"}, "organization": {"fullName": "University of Pennsylvania", "class": "OTHER"}, "briefTitle": "Furosemide for Accelerated Recovery of Blood Pressure Postpartum", "officialTitle": "Furosemide for Accelerated Recovery of Blood Pressure Postpartum", "acronym": "ForBP"}, "statusModule": {"statusVerifiedDate": "2020-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2018-06-20", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-12-04", "type": "ACTUAL"}, "completionDateStruct": {"date": "2020-02-05", "type": "ACTUAL"}, "studyFirstSubmitDate": "2018-06-01", "studyFirstSubmitQcDate": "2018-06-01", "studyFirstPostDateStruct": {"date": "2018-06-14", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2020-08-02", "resultsFirstSubmitQcDate": "2020-08-26", "resultsFirstPostDateStruct": {"date": "2020-09-10", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-08-26", "lastUpdatePostDateStruct": {"date": "2020-09-10", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "PRINCIPAL_INVESTIGATOR", "investigatorFullName": "Lisa Levine", "investigatorTitle": "Assistant Professor", "investigatorAffiliation": "University of Pennsylvania"}, "leadSponsor": {"name": "University of Pennsylvania", "class": "OTHER"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false, "isUsExport": true}, "descriptionModule": {"briefSummary": "A randomized, double-blind, placebo-controlled single center investigation of furosemide's effect on postpartum blood pressure control in pregnancies affected by hypertensive disorders of pregnancy", "detailedDescription": "Hypertensive disorders of pregnancy are recognized causes of significant maternal/fetal morbidity and mortality, accounting for approximately 18% of maternal deaths worldwide. While significant research has been done on the evaluation and management of hypertension during pregnancy, studies of postpartum hypertension (PPHTN) are usually limited by their retrospective design and focus on inpatients in the immediate postpartum period (2-6 days), or patients who were readmitted due to complications related to hypertension. Few studies have investigated the incidence and proper management of hypertension in the postpartum period. Furthermore, in the United Kingdom, a review of maternal deaths determined that 10% were related to hypertensive disorders in pregnancy (HDP) in the postpartum period. Postpartum hypertension is also the cause of approximately 27% of readmissions to the hospital. These studies clearly show that PPHTN is associated with significant morbidity and that it is important to develop interventions that can reduce its effects.\n\nIn patients with HDP, postpartum blood pressure has been shown to decrease in the first 48 hours postpartum only to then increase in days 3-6 postpartum. This phenomenon is thought to be secondary to large fluid shifts, both secondary from fluid retention during the pregnant state as well as from fluids given intrapartum. Furthermore, large volumes of sodium are also mobilized into the intravascular compartment at this time. Given the latter, furosemide, a loop diuretic that mobilizes sodium and fluid excretion has been posed as a method to prevent severe range blood pressures and their associated maternal morbidity in the postpartum period."}, "conditionsModule": {"conditions": ["Hypertension, Pregnancy-Induced"], "keywords": ["Furosemide", "Postpartum", "Hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "Double blind, randomized, placebo control design", "primaryPurpose": "PREVENTION", "maskingInfo": {"masking": "QUADRUPLE", "maskingDescription": "Study medication (furosemide) and placebo will be stored at room temperature at the University of Pennsylvania research pharmacy. Pharmacy will be responsible for labeling and randomizing the medications.", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 384, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Oral furosemide", "type": "EXPERIMENTAL", "description": "Oral furosemide 20 mg/day for a total of 5 consecutive doses.", "interventionNames": ["Drug: Oral furosemide"]}, {"label": "Placebo Oral Tablet", "type": "PLACEBO_COMPARATOR", "description": "Placebo once per day for a total of 5 consecutive doses.", "interventionNames": ["Drug: Placebo Oral Tablet"]}], "interventions": [{"type": "DRUG", "name": "Oral furosemide", "description": "Furosemide (Lasix), 20 milligram, PO, PO, daily", "armGroupLabels": ["Oral furosemide"]}, {"type": "DRUG", "name": "Placebo Oral Tablet", "description": "Placebo, PO, daily", "armGroupLabels": ["Placebo Oral Tablet"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Persistently Elevated Blood Pressures 7 Days Postpartum", "description": "To compare the rate of persistently elevated blood pressures (\\>140/90) in women that receive a five day furosemide course compared to those that receive placebo.", "timeFrame": "0-7 days postpartum"}, {"measure": "Time to Resolution", "description": "To compare the time (days) required to achieve a resolution of elevated blood pressure, adjusted for mode of delivery.", "timeFrame": "0-14 days postpartum"}], "secondaryOutcomes": [{"measure": "Postpartum Readmission", "description": "Number of subjects with one or more readmission/ER visit that were hypertension related", "timeFrame": "0-6 weeks postpartum"}, {"measure": "Number of Subjects Who Had Severe Hypertension Postpartum", "description": "Number of women who had severe hypertension (systolic blood pressure\\>160 millimeters of mercury or diastolic blood pressure\\>110 millimeters of mercury) postpartum", "timeFrame": "0-6 weeks postpartum"}, {"measure": "Postpartum Length of Stay", "description": "Number of days postpartum participants stayed in the hospital", "timeFrame": "0-6 weeks postpartum"}, {"measure": "Subjects With Complications During Hospitalization", "description": "Subjects with complications during hospitalization related to hypertensive disorders of pregnancy.", "timeFrame": "0-6 weeks postpartum"}, {"measure": "Number of Subjects Experiencing One or More Adverse Effects", "description": "Number of subjects experiencing one or more adverse effects secondary to furosemide", "timeFrame": "0-6 weeks postpartum"}, {"measure": "Number of Subjects That Required for Additional Antihypertensives", "description": "Number of subjects that required additional hypertensive medication after discharge", "timeFrame": "0 to 6 weeks post-partum"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Hypertensive disorder of pregnancy diagnosed antepartum or intrapartum\n* Gestational hypertension\n* Pre-eclampsia with or without severe features\n* Superimposed pre-eclampsia with or without severe features\n* New diagnosis of HDP within 24 hours from delivery\n* Postpartum, delivery \u2265 20 weeks estimated gestational age\n* Age \u226518 years old\n\nExclusion Criteria:\n\n* History of allergic reaction to furosemide\n* High risk comorbidities for which treatment may be indicated or contraindicated: class C or higher diabetes mellitus, chronic kidney disease or baseline creatinine \\>1.2, cardiac disorders including cardiomyopathy, congenital heart disease, angina or coronary heart disease, rheumatic disease (lupus), sickle cell disease\n* Baseline labs with K \\<3\n* Use of furosemide or other diuretics antepartum or intrapartum\n* Use of ototoxic agents including aminoglycosides (ie, Gentamicin for \\>1 dose), cephalosporins (ie Ancef \\>1 dose),\n* Patient unstable for protocol per investigator's judgement", "healthyVolunteers": false, "sex": "FEMALE", "minimumAge": "18 Years", "maximumAge": "55 Years", "stdAges": ["ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Lisa Levine, MD", "affiliation": "University of Pennsylvania", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Hospital of the University of Pennsylvania", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19104", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}]}, "referencesModule": {"references": [{"pmid": "33550824", "type": "DERIVED", "citation": "Lopes Perdigao J, Lewey J, Hirshberg A, Koelper N, Srinivas SK, Elovitz MA, Levine LD. Furosemide for Accelerated Recovery of Blood Pressure Postpartum in women with a hypertensive disorder of pregnancy: A Randomized Controlled Trial. Hypertension. 2021 May 5;77(5):1517-1524. doi: 10.1161/HYPERTENSIONAHA.120.16133. Epub 2021 Feb 8."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Oral Furosemide", "description": "Oral furosemide 20 mg/day for a total of 5 consecutive doses.\n\nOral furosemide: Furosemide (Lasix), 20 milligram, PO, PO, daily"}, {"id": "FG001", "title": "Placebo Oral Tablet", "description": "Placebo once per day for a total of 5 consecutive doses.\n\nPlacebo Oral Tablet: Placebo, PO, daily"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "192"}, {"groupId": "FG001", "numSubjects": "192"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "168"}, {"groupId": "FG001", "numSubjects": "163"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "24"}, {"groupId": "FG001", "numSubjects": "29"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Oral Furosemide", "description": "Oral tablet of furosemide 20 mg once daily for a total of 5 consecutive doses."}, {"id": "BG001", "title": "Placebo Oral Tablet", "description": "Oral tablet of placebo once daily for a total of 5 consecutive doses."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "192"}, {"groupId": "BG001", "value": "192"}, {"groupId": "BG002", "value": "384"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "27", "lowerLimit": "22", "upperLimit": "32"}, {"groupId": "BG001", "value": "27", "lowerLimit": "23", "upperLimit": "33"}, {"groupId": "BG002", "value": "27", "lowerLimit": "22", "upperLimit": "33"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "192"}, {"groupId": "BG001", "value": "192"}, {"groupId": "BG002", "value": "384"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "151"}, {"groupId": "BG001", "value": "138"}, {"groupId": "BG002", "value": "289"}]}]}, {"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "47"}, {"groupId": "BG002", "value": "77"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "18"}]}]}]}, {"title": "Hypertensive Disorders of Pregnancy (HDP)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Non-severe", "measurements": [{"groupId": "BG000", "value": "128"}, {"groupId": "BG001", "value": "133"}, {"groupId": "BG002", "value": "261"}]}, {"title": "Severe", "measurements": [{"groupId": "BG000", "value": "64"}, {"groupId": "BG001", "value": "59"}, {"groupId": "BG002", "value": "123"}]}]}]}, {"title": "Gestational age at delivery", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "weeks", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "38.6", "lowerLimit": "37.3", "upperLimit": "39.7"}, {"groupId": "BG001", "value": "38.4", "lowerLimit": "37.3", "upperLimit": "39.7"}, {"groupId": "BG002", "value": "38.5", "lowerLimit": "37.3", "upperLimit": "39.7"}]}]}]}, {"title": "Cesarean delivery", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55"}, {"groupId": "BG001", "value": "38"}, {"groupId": "BG002", "value": "93"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Persistently Elevated Blood Pressures 7 Days Postpartum", "description": "To compare the rate of persistently elevated blood pressures (\\>140/90) in women that receive a five day furosemide course compared to those that receive placebo.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "0-7 days postpartum", "groups": [{"id": "OG000", "title": "Oral Furosemide", "description": "Oral furosemide 20 mg/day for a total of 5 consecutive doses.\n\nOral furosemide: Furosemide (Lasix), 20 milligram, PO, PO, daily"}, {"id": "OG001", "title": "Placebo Oral Tablet", "description": "Placebo once per day for a total of 5 consecutive doses.\n\nPlacebo Oral Tablet: Placebo, PO, daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "168"}, {"groupId": "OG001", "value": "163"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10"}, {"groupId": "OG001", "value": "23"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.03", "statisticalMethod": "Regression, Linear", "paramType": "Risk Ratio (RR)", "paramValue": "0.40", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.20", "ciUpperLimit": "0.81"}]}, {"type": "PRIMARY", "title": "Time to Resolution", "description": "To compare the time (days) required to achieve a resolution of elevated blood pressure, adjusted for mode of delivery.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "days", "timeFrame": "0-14 days postpartum", "groups": [{"id": "OG000", "title": "Oral Furosemide", "description": "Oral furosemide 20 mg/day for a total of 5 consecutive doses.\n\nOral furosemide: Furosemide (Lasix), 20 milligram, PO, PO, daily"}, {"id": "OG001", "title": "Placebo Oral Tablet", "description": "Placebo once per day for a total of 5 consecutive doses.\n\nPlacebo Oral Tablet: Placebo, PO, daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "168"}, {"groupId": "OG001", "value": "163"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "10", "lowerLimit": "6.25", "upperLimit": "12.5"}, {"groupId": "OG001", "value": "10.5", "lowerLimit": "6.5", "upperLimit": "12.5"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.12", "statisticalMethod": "Regression, Cox", "paramType": "Hazard Ratio (HR)", "paramValue": "1.20", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.95", "ciUpperLimit": "1.51"}]}, {"type": "SECONDARY", "title": "Postpartum Readmission", "description": "Number of subjects with one or more readmission/ER visit that were hypertension related", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "0-6 weeks postpartum", "groups": [{"id": "OG000", "title": "Oral Furosemide", "description": "Oral furosemide 20 mg/day for a total of 5 consecutive doses.\n\nOral furosemide: Furosemide (Lasix), 20 milligram, PO, PO, daily"}, {"id": "OG001", "title": "Placebo Oral Tablet", "description": "Placebo once per day for a total of 5 consecutive doses.\n\nPlacebo Oral Tablet: Placebo, PO, daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "168"}, {"groupId": "OG001", "value": "163"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "16"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.14", "statisticalMethod": "Chi-squared", "paramType": "Risk Ratio (RR)", "paramValue": "0.55", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.25", "ciUpperLimit": "1.21"}]}, {"type": "SECONDARY", "title": "Number of Subjects Who Had Severe Hypertension Postpartum", "description": "Number of women who had severe hypertension (systolic blood pressure\\>160 millimeters of mercury or diastolic blood pressure\\>110 millimeters of mercury) postpartum", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "0-6 weeks postpartum", "groups": [{"id": "OG000", "title": "Oral Furosemide", "description": "Oral furosemide 20 mg/day for a total of 5 consecutive doses.\n\nOral furosemide: Furosemide (Lasix), 20 milligram, PO, PO, daily"}, {"id": "OG001", "title": "Placebo Oral Tablet", "description": "Placebo once per day for a total of 5 consecutive doses.\n\nPlacebo Oral Tablet: Placebo, PO, daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "168"}, {"groupId": "OG001", "value": "163"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "81"}, {"groupId": "OG001", "value": "86"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.36", "statisticalMethod": "Chi-squared", "paramType": "Risk Ratio (RR)", "paramValue": "0.87", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.64", "ciUpperLimit": "1.18"}]}, {"type": "SECONDARY", "title": "Postpartum Length of Stay", "description": "Number of days postpartum participants stayed in the hospital", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Inter-Quartile Range", "unitOfMeasure": "Days", "timeFrame": "0-6 weeks postpartum", "groups": [{"id": "OG000", "title": "Oral Furosemide", "description": "Oral furosemide 20 mg/day for a total of 5 consecutive doses.\n\nOral furosemide: Furosemide (Lasix), 20 milligram, PO, PO, daily"}, {"id": "OG001", "title": "Placebo Oral Tablet", "description": "Placebo once per day for a total of 5 consecutive doses.\n\nPlacebo Oral Tablet: Placebo, PO, daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "168"}, {"groupId": "OG001", "value": "163"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "2", "lowerLimit": "2", "upperLimit": "3"}, {"groupId": "OG001", "value": "2", "lowerLimit": "2", "upperLimit": "2"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.76", "statisticalMethod": "Regression, Linear", "paramType": "Risk Ratio (RR)", "paramValue": "0.02", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.09", "ciUpperLimit": ".13"}]}, {"type": "SECONDARY", "title": "Subjects With Complications During Hospitalization", "description": "Subjects with complications during hospitalization related to hypertensive disorders of pregnancy.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "0-6 weeks postpartum", "groups": [{"id": "OG000", "title": "Oral Furosemide", "description": "Oral furosemide 20 mg/day for a total of 5 consecutive doses.\n\nOral furosemide: Furosemide (Lasix), 20 milligram, PO, PO, daily"}, {"id": "OG001", "title": "Placebo Oral Tablet", "description": "Placebo once per day for a total of 5 consecutive doses.\n\nPlacebo Oral Tablet: Placebo, PO, daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "192"}, {"groupId": "OG001", "value": "192"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.62", "statisticalMethod": "Fisher Exact"}]}, {"type": "SECONDARY", "title": "Number of Subjects Experiencing One or More Adverse Effects", "description": "Number of subjects experiencing one or more adverse effects secondary to furosemide", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "0-6 weeks postpartum", "groups": [{"id": "OG000", "title": "Oral Furosemide", "description": "Oral furosemide 20 mg/day for a total of 5 consecutive doses.\n\nOral furosemide: Furosemide (Lasix), 20 milligram, PO, PO, daily"}, {"id": "OG001", "title": "Placebo Oral Tablet", "description": "Placebo once per day for a total of 5 consecutive doses.\n\nPlacebo Oral Tablet: Placebo, PO, daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "192"}, {"groupId": "OG001", "value": "192"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "paramType": "Risk Ratio (RR)", "paramValue": "3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.32", "ciUpperLimit": "28.59"}]}, {"type": "SECONDARY", "title": "Number of Subjects That Required for Additional Antihypertensives", "description": "Number of subjects that required additional hypertensive medication after discharge", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "0 to 6 weeks post-partum", "groups": [{"id": "OG000", "title": "Oral Furosemide", "description": "Oral furosemide 20 mg/day for a total of 5 consecutive doses.\n\nOral furosemide: Furosemide (Lasix), 20 milligram, PO, PO, daily"}, {"id": "OG001", "title": "Placebo Oral Tablet", "description": "Placebo once per day for a total of 5 consecutive doses.\n\nPlacebo Oral Tablet: Placebo, PO, daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "192"}, {"groupId": "OG001", "value": "192"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "25"}, {"groupId": "OG001", "value": "39"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.03", "statisticalMethod": "Chi-squared", "paramType": "Risk Ratio (RR)", "paramValue": "0.61", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.39", "ciUpperLimit": "0.96"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Over 6 weeks postpartum", "eventGroups": [{"id": "EG000", "title": "Oral Furosemide", "description": "Oral furosemide 20 mg/day for a total of 5 consecutive doses.\n\nOral furosemide: Furosemide (Lasix), 20 milligram, PO, PO, daily", "deathsNumAffected": 0, "deathsNumAtRisk": 192, "seriousNumAffected": 0, "seriousNumAtRisk": 192, "otherNumAffected": 3, "otherNumAtRisk": 192}, {"id": "EG001", "title": "Placebo Oral Tablet", "description": "Placebo once per day for a total of 5 consecutive doses.\n\nPlacebo Oral Tablet: Placebo, PO, daily", "deathsNumAffected": 0, "deathsNumAtRisk": 192, "seriousNumAffected": 0, "seriousNumAtRisk": 192, "otherNumAffected": 1, "otherNumAtRisk": 192}], "otherEvents": [{"term": "Pulmonary edema", "organSystem": "Pregnancy, puerperium and perinatal conditions", "assessmentType": "SYSTEMATIC_ASSESSMENT", "notes": "Pulmonary edema", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 192}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 192}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Dr Lisa Levine", "organization": "University of Pennsylvania", "email": "lisa.levine@pennmedicine.upenn.edu", "phone": "215-662-6913"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2018-07-19", "uploadDate": "2020-08-01T10:54", "filename": "Prot_SAP_000.pdf", "size": 258664}, {"typeAbbrev": "ICF", "hasProtocol": false, "hasSap": false, "hasIcf": true, "label": "Informed Consent Form", "date": "2018-09-13", "uploadDate": "2020-08-01T10:54", "filename": "ICF_001.pdf", "size": 225643}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2020-08-17", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000046110", "term": "Hypertension, Pregnancy-Induced"}, {"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000011248", "term": "Pregnancy Complications"}, {"id": "D000005261", "term": "Female Urogenital Diseases and Pregnancy Complications"}, {"id": "D000091642", "term": "Urogenital Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M25635", "name": "Hypertension, Pregnancy-Induced", "asFound": "Hypertension, Pregnancy-Induced", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "M14127", "name": "Pregnancy Complications", "relevance": "LOW"}, {"id": "M2875", "name": "Urogenital Diseases", "relevance": "LOW"}, {"id": "M27093", "name": "Female Urogenital Diseases", "relevance": "LOW"}, {"id": "M8399", "name": "Female Urogenital Diseases and Pregnancy Complications", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BXS", "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000005665", "term": "Furosemide"}], "ancestors": [{"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000049994", "term": "Sodium Potassium Chloride Symporter Inhibitors"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M8784", "name": "Furosemide", "asFound": "48 hours", "relevance": "HIGH"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26153", "name": "Sodium Potassium Chloride Symporter Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}